Provided By Clinical Care Options (All links open into new windows)
Highlights From EASL 2012
Source: CCO Independent Conference Coverage of the 2012 Annual Meeting of the European Association for the Study of the Liver*
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.
Capsule Summaries
- ATOMIC: GS-7977 Plus PegIFN/RBV for 12 or 24 Weeks of Therapy Achieves Rapid, Sustained Viral Suppression in Treatment-Naive Patients With Genotype 1 HCV
- ASPIRE: TMC435 Plus PegIFN/RBV Significantly Improves SVR24 Rates Over PegIFN/RBV Alone in Patients With Genotype 1 HCV Who Failed Previous PegIFN/RBV Therapy
- In Interim Analysis of Early Access Cohort, Telaprevir- and Boceprevir-Based Regimens Associated With Poor Safety but High On-Treatment Efficacy in Treatment-Experienced Genotype 1 Patients With Compensated Cirrhosis
- EMERGE: PegIFN lambda-1a Associated With Comparable SVR Rates, Less Dose Modification vs PegIFN alfa-2a in Treatment-Naive Patients With Genotype 2/3 HCV
- PROVIDE Interim Results: Substantial Proportion of Genotype 1 HCV Previous PegIFN/RBV Null Responders Achieved SVR Upon Retreatment With Boceprevir Plus PegIFN/RBV
- Quadruple Therapy With Tegobuvir and GS-9256 Plus PegIFN/RBV Shows Potent Viral Suppression With Shortened Therapy in Genotype 1 HCV, but Safety Concerns Preclude Further Development of the Combination
- Pilot Study: Interferon-Free Regimen of ABT-450/Ritonavir, ABT-072, ABT-450, and Ribavirin Achieved SVR12 in 91% of Noncirrhotic Treatment-Naive Genotype 1 HCV Patients With IL28B CC Genotype
- Dual Oral Therapy With Daclatasvir and Asunaprevir Achieves 77% SVR in Genotype 1b HCV–Infected Patients With Previous Null Response, Medical Ineligibility, or Intolerance to Peginterferon/Ribavirin
- Boceprevir or Telaprevir in Combination With PegIFN/RBV Improved On-Treatment Virologic Response Rates in Patients With Severe Genotype 1 Hepatitis C Recurrence Following Liver Transplantation vs Historical Treatment With PegIFN/RBV
- Boceprevir Plus PegIFN/RBV Appears Safe, Effective in Genotype 1 HCV Therapy-Naive, HIV-Coinfected Patients on Stable Antiretroviral Therapy
- Retrospective Analysis of Viral Kinetics During Treatment With Telaprevir Plus PegIFN/RBV Underscores Validity of Futility Rules
- Miravirsen Safe, Well Tolerated With Durable Antiviral Activity in Phase IIa Trial in Treatment-Naive Patients With Chronic Genotype 1 HCV
- SOUND-C2 Interim Results: High Efficacy, Good Safety Profile of IFN-Free BI 201335, BI 207127, and RBV Combination Therapy in Treatment-Naive Patients With Genotype 1 HCV
- BRISK-PS: Brivanib Fails to Improve OS in Patients With Advanced HCC Who Failed Sorafenib
- Co-Pilot Study: IFN-Free Regimen of ABT-450/Ritonavir, ABT-333, and Ribavirin Achieved 12-Week SVR Rates > 90% in Genotype 1 HCV
- VITAL-1: Interim Results Indicate Alisporivir Plus Ribavirin Achieved High SVR Rates With or Without Addition of PegIFN in Treatment-Naive Patients With Genotype 2/3 HCV Infection
- INFORM-SVR: Safety and Efficacy of Interferon-Free Combination of Mericitabine, Ritonavir-Boosted Danoprevir, and Ribavirin in Treatment-Naive Patients With Genotype 1b HCV
- SVR Rates Similar in Boceprevir-Treated Patients Randomized to RBV Dose Reduction or Erythropoietin for Anemia Management in Prospective Trial
- High SVR Rates and Acceptable Safety Profile With Interferon-Free, All-Oral, Quad Regimen of GS-5885, GS-9451, Tegobuvir, and Ribavirin in Treatment-Naive Patients With Genotype 1 HCV Infection
- Interferon-Free Combination of Daclatasvir (NS5A Inhibitor) Plus GS-7977 (NS5B Inhibitor) Demonstrates High Rates of SVR4 in Treatment-Naive Patients With Chronic Genotype 1, 2, or 3 HCV Infection
Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials
No comments:
Post a Comment